Optimisation of SARS-CoV-2 culture from clinical samples for clinical trial applications
Abstract Clinical trials of SARS-CoV-2 therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using RT-qPCR, which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardised for use as clinical trial endpoints.We report optimisation of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-ACE2-TMPRSS2 (VAT) cells in combination with RT-qPCR of culture supernatants from the first passage provides the greatest overall detection of Delta viral replication (22/32, 68.8%), being able to identify viable virus in 83.3% (20/24) of clinical samples with initial Ct values <30. Likewise, we demonstrate that RT-qPCR using culture supernatants from the first passage of Vero hSLAM cells provides the highest overall detection of Omicron viral replication (9/31, 29%), detecting live virus in 39.1% (9/23) of clinical samples with initial Ct values < 25. This assessment demonstrates that combining RT-qPCR with virological end point analysis has utility in clinical trials of therapeutics for SARS-CoV-2; however, techniques may require optimising based on dominant circulating strain..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 28. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Wooding, Dominic [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2024.03.25.24304829 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI043057136 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI043057136 | ||
| 003 | DE-627 | ||
| 005 | 20240329090632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240327s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2024.03.25.24304829 |2 doi | |
| 035 | |a (DE-627)XBI043057136 | ||
| 035 | |a (biorXiv)10.1101/2024.03.25.24304829 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Wooding, Dominic |e verfasserin |0 (orcid)0000-0002-9985-0413 |4 aut | |
| 245 | 1 | 0 | |a Optimisation of SARS-CoV-2 culture from clinical samples for clinical trial applications |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Clinical trials of SARS-CoV-2 therapeutics often include virological secondary endpoints to compare viral clearance and viral load reduction between treatment and placebo arms. This is typically achieved using RT-qPCR, which cannot differentiate replicant competent virus from non-viable virus or free RNA, limiting its utility as an endpoint. Culture based methods for SARS-CoV-2 exist; however, these are often insensitive and poorly standardised for use as clinical trial endpoints.We report optimisation of a culture-based approach evaluating three cell lines, three detection methods, and key culture parameters. We show that Vero-ACE2-TMPRSS2 (VAT) cells in combination with RT-qPCR of culture supernatants from the first passage provides the greatest overall detection of Delta viral replication (22/32, 68.8%), being able to identify viable virus in 83.3% (20/24) of clinical samples with initial Ct values <30. Likewise, we demonstrate that RT-qPCR using culture supernatants from the first passage of Vero hSLAM cells provides the highest overall detection of Omicron viral replication (9/31, 29%), detecting live virus in 39.1% (9/23) of clinical samples with initial Ct values < 25. This assessment demonstrates that combining RT-qPCR with virological end point analysis has utility in clinical trials of therapeutics for SARS-CoV-2; however, techniques may require optimising based on dominant circulating strain. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Buist, Kate |0 (orcid)0000-0002-8004-6329 |4 aut | |
| 700 | 1 | |a Romero-Ramirez, Alessandra |0 (orcid)0000-0002-8610-7815 |4 aut | |
| 700 | 1 | |a Savage, Helen |4 aut | |
| 700 | 1 | |a Watkins, Rachel |4 aut | |
| 700 | 1 | |a Bengey, Daisy |0 (orcid)0000-0002-0045-0218 |4 aut | |
| 700 | 1 | |a Greenland-Bews, Caitlin |0 (orcid)0000-0003-3374-1385 |4 aut | |
| 700 | 1 | |a Thompson, Caitlin R |4 aut | |
| 700 | 1 | |a Kontogianni, Nadia |0 (orcid)0000-0002-5353-3682 |4 aut | |
| 700 | 1 | |a Body, Richard |0 (orcid)0000-0001-9089-8130 |4 aut | |
| 700 | 1 | |a Hayward, Gail |0 (orcid)0000-0003-0852-627X |4 aut | |
| 700 | 1 | |a Byrne, Rachel L |4 aut | |
| 700 | 1 | |a Gould, Susan |4 aut | |
| 700 | 1 | |a Group, CONDOR Steering |4 aut | |
| 700 | 1 | |a Myerscough, Christopher |4 aut | |
| 700 | 1 | |a Atkinson, Barry |0 (orcid)0000-0002-1348-7204 |4 aut | |
| 700 | 1 | |a Shaw, Victoria |4 aut | |
| 700 | 1 | |a Greenhalf, Bill |4 aut | |
| 700 | 1 | |a Adams, Emily |4 aut | |
| 700 | 1 | |a Cubas-Atienzar, Ana |0 (orcid)0000-0002-9604-124X |4 aut | |
| 700 | 1 | |a Khoo, Saye |0 (orcid)0000-0002-2769-0967 |4 aut | |
| 700 | 1 | |a Fletcher, Tom |0 (orcid)0000-0002-3712-415X |4 aut | |
| 700 | 1 | |a Edwards, Thomas |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 28. März |
| 773 | 1 | 8 | |g year:2024 |g day:28 |g month:03 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2024.03.25.24304829 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 28 |c 03 | ||